SCHEMBL13367642

SCHEMBL13367642

Cc1ccc2c(c1)OC(C)(C)C(=O)N2CCF

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NR3C2 P08235 1/20 0.39
POLB P06746 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 2/20 0.37
RECQL P46063 1/20 0.37
ELANE P08246 2/20 0.36
PRTN3 P24158 2/20 0.36
CTSG P08311 1/20 0.36
KDM4E B2RXH2 1/20 0.36
F2 P00734 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXRA P19793 2/20 0.36
REN P00797 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15786429 0.93 REN (0.38) MAPTHPGDTSHRNPSR1NR3C2
SCHEMBL16601598 0.89 ALDH1A1 (0.40) MAPTHPGDTSHRNPSR1NR3C2
SCHEMBL13367651 0.85 RXRA (0.43) MAPTHPGDTSHRNPSR1NR3C2
SCHEMBL16601579 0.85 MAPT (0.38) MAPTHPGDTSHRNPSR1NR3C2
SCHEMBL13961978 0.84 NR3C2 (0.39) MAPTHPGDTSHRNPSR1NR3C2
SCHEMBL13340990 0.82 SLC9A1 (0.37) MAPTNR3C2POLBMEN1KMT2A
SCHEMBL90227 0.82 MAPT (0.44) MAPTHPGDTSHRNPSR1POLB
SCHEMBL15161226 0.80 PDE3B (0.49) MAPTHPGDTSHRNPSR1NR3C2
SCHEMBL15786401 0.80 MAPT (0.40) MAPTHPGDTSHRNPSR1POLB
SCHEMBL13960957 0.79 NR3C2 (0.37) MAPTNR3C2POLBALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ MAPT 3398/4885HPGD 1434/4885TSHR 2897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.